1. Home
  2. EOCN vs GOVX Comparison

EOCN vs GOVX Comparison

Compare EOCN & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EOCN

Eocene Ltd. Ordinary Shares

N/A

Current Price

$3.50

Market Cap

3.6M

Sector

Health Care

ML Signal

N/A

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$0.36

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EOCN
GOVX
Founded
N/A
2001
Country
Israel
United States
Employees
6
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.8M
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
EOCN
GOVX
Price
$3.50
$0.36
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
2.2K
552.9K
Earning Date
N/A
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,489,145.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.33
$0.12
52 Week High
$3.66
$4.40

Technical Indicators

Market Signals
Indicator
EOCN
GOVX
Relative Strength Index (RSI) N/A 22.72
Support Level N/A $0.16
Resistance Level N/A $0.86
Average True Range (ATR) 0.00 0.04
MACD 0.00 -0.01
Stochastic Oscillator 0.00 2.66

Price Performance

Historical Comparison
EOCN
GOVX

About EOCN Eocene Ltd. Ordinary Shares

Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Share on Social Networks: